TY - JOUR
T1 - Current whole-body MRI applications in the neurofibromatosis
T2 - NF1, NF2, and schwannomatosis
AU - Ahlawat, Shivani
AU - Fayad, Laura M.
AU - Khan, Muhammad Shayan
AU - Bredella, Miriam A.
AU - Harris, Gordon J.
AU - Evans, D. Gareth
AU - Farschtschi, Said
AU - Jacobs, Michael A.
AU - Chhabra, Avneesh
AU - Salamon, Johannes M.
AU - Wenzel, Ralph
AU - Mautner, Victor F.
AU - Dombi, Eva
AU - Cai, Wenli
AU - Plotkin, Scott R.
AU - Blakeley, Jaishri O.
N1 - Publisher Copyright:
© 2016 American Academy of Neurology.
PY - 2016/8/16
Y1 - 2016/8/16
N2 - Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection ofWBtumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.
AB - Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection ofWBtumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.
UR - http://www.scopus.com/inward/record.url?scp=85003723261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85003723261&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002929
DO - 10.1212/WNL.0000000000002929
M3 - Article
C2 - 27527647
AN - SCOPUS:85003723261
SN - 0028-3878
VL - 87
SP - S31-S39
JO - Neurology
JF - Neurology
IS - 7
ER -